ArticlePloS one2018
Bacteriophage cocktail for biocontrol of Escherichia coli O157:H7: Stability and potential allergenicity study.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Characterization and genome analysis of virulent phage against phytopathogen Pantoea ananatis and its potential biocontrol application.BMC microbiology · 2026Article
- Limitations and safety aspects related to the use of bacteriophages in food production.FEMS microbiology reviews · 2026Article
- Genomic and functional characterization of a novel lytic phage vB-AbaM-fThrA with anti-biofilm activity against CR-MDR Acinetobacter baumannii.BMC microbiology · 2025Article
- Shiga toxin-producingMicrobiology and molecular biology reviews : MMBR · 2025Review
- Isolation and characterization of phages ΦZC2 and ΦZC3 against carbapenem-resistant Acinetobacter baumannii, and efficacy of ΦZC3 on A549 cells.Virology journal · 2025Article
- A novelFrontiers in microbiology · 2025Article
- Isolation, characterization, therapeutic and prophylactic applications of a lytic bacteriophage to combat multi-drug resistance Shigella flexneri: an animal study model.GMS hygiene and infection control · 2025Article
- Combating antibiotic resistance in a one health context: a plethora of frontiers.One health outlook · 2024Review
- Nanomechanical resilience and thermal stability of RSJ2 phage.Scientific reports · 2024Article
- Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease.Frontiers in immunology · 2024Review
- Safety Properties ofFoods (Basel, Switzerland) · 2023Review
- Selection and characterization of bacteriophages specific toVeterinary world · 2022Article
- Article
- Evaluating the Phenotypic and Genomic Characterization of Some Egyptian Phages Infecting Shiga Toxin-ProducingBiology · 2022Article
- Thermoresponsive C22 phage stiffness modulates the phage infectivity.Scientific reports · 2022Article
- Biocontrol Approaches againstFoods (Basel, Switzerland) · 2022Review
- APTC-EC-2A: A Lytic Phage Targeting Multidrug ResistantMicroorganisms · 2022Article
- Prospects of bacteriophage collections in disinfectant applications.Veterinary world · 2022Article
- Biocontrol ofIranian journal of veterinary research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli O157:H7 has become a global public health and a food safety problem. Despite the implementation of control strategies that guarantee the safety in various products, outbreaks persist and new alternatives are necessary to reduce this pathogen along the food chain. Recently, our group isolated and characterised lytic bacteriophages against E. coli O157:H7 with potential to be used as biocontrol agents in food. To this end, phages need certain requirements to allow their manufacture and application. The aim of this study was to determine the physical stability and allergenic potential of free and microencapsulated (ME) bacteriophage cocktails against E. coli O157:H7. In vitro and in vivo studies were performed to determine phage survival under different pH, gastrointestinal conditions, temperature and UV light intensities. Results showed that the stability of ME phages was significantly (P<0.05) higher than free phages after ultraviolet irradiation, pH conditions between 3 to 7, and exposure to temperatures between at -80°C and 70°C. Both formulations were highly sensitive to very low pH in simulated gastric fluid, but stable in bile salts. In vivo studies in mice confirmed these phages passed through the gastrointestinal tract and were excreted in faeces. In silico, full-length alignment analysis showed that all phage proteins were negative for allergenic potential, but different predicting criteria classified seven phage proteins with a very low probability to be an allergen. In conclusion, these data demonstrated that microencapsulation provided a greater stability to phage formulation under stress conditions and assure a more suitable commercial formulation for the biological control of E. coli O157:H7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.